LATEST ROUND
Series C
$150M · 2026-09-08
RAISED ON RECORD · USD
$150M
1 of 2 verified rounds state an amount · $300M to date, as reported
INVESTORS
12
2 leads
SOURCES
15
from 15 publishers
14 sources
The source also says Forus has raised more than $300 million in total funding; this is total funding to date, not the Series C amount, so it is not reported as the financing total.; not on the page it cites, so not applied: date
1 source
The source states the Series B, announcement date, lead investor, and other investors, but does not state the amount or Forus's headquarters. The “Based in Bay Area” entries refer to Accel team members, not Forus.
Published by hand (accel.com): "We are proud to announce that Accel is leading Forus’s Series B financing, alongside our friends at Thrive and General Catalyst.": brand backfill hand check: the page states the round (announced)
Valuation none read as $1 billion (forbes.com): "Forus reached $1 billion valuation by dealing with the unglamorous admin work of processing scripts so patients can get the drugs they need.": stated in the announcement
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $150M $300M to date at $3B valuation | 2026-09-08 | Bain Capital Ventures | No recent discussion |
14 sources [ VERIFIED ] read against 1 of 14 sources The source also says Forus has raised more than $300 million in total funding; this is total funding to date, not the Series C amount, so it is not reported as the financing total.; not on the page it cites, so not applied: date | ||||
Forus builds an AI-powered network for doctors, pharmacies, payers, biopharma companies and patients that automates the administrative path from prescription to medication access.
Forus targets a major bottleneck in healthcare: the forms, insurance authorizations, appeals, affordability work and pharmacy routing that can leave more than a third of patients prescribed high-cost or complex medicines without a first dose and can delay treatment for weeks or months. Its funding is a bet that an AI agent assigned to every prescription can scale a national network—already used by thousands of practices, covering all 50 states and 85% of U.S. residential ZIP codes—while its resulting access data helps biopharma companies bring therapies to patients more effectively.
Checked against 10 sources on Sep 23
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | n/a at $1 billion valuation | 2026-05-12 | Accel | No recent discussion |
1 source [ VERIFIED ] read against 1 source The source states the Series B, announcement date, lead investor, and other investors, but does not state the amount or Forus's headquarters. The “Based in Bay Area” entries refer to Accel team members, not Forus. Published by hand (accel.com): "We are proud to announce that Accel is leading Forus’s Series B financing, alongside our friends at Thrive and General Catalyst.": brand backfill hand check: the page states the round (announced) Valuation none read as $1 billion (forbes.com): "Forus reached $1 billion valuation by dealing with the unglamorous admin work of processing scripts so patients can get the drugs they need.": stated in the announcement [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: accel.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||